BGLC - CIK 0001737523
BioNexus Gene Lab Corp (BGLC) reported revenue of $7.42M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $7.42M | -21.9% |
| FY 2024 | $9.51M | -2.7% |
| FY 2023 | $9.77M | -10.6% |
| FY 2022 | $10.93M | -18.2% |
| FY 2021 | $13.36M | +17.3% |
| FY 2020 | $11.39M | +8872.0% |
| FY 2019 | $126.95K | -40.2% |
| FY 2018 | $212.33K | - |
BioNexus Gene Lab Corp (BGLC) reported revenue of $7.42M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2018 and fiscal 2025, BioNexus Gene Lab Corp's revenue grew from $212.33K to $7.42M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.